371 related articles for article (PubMed ID: 33275747)
1. Future of CAR T cells in multiple myeloma.
Wudhikarn K; Mailankody S; Smith EL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):272-279. PubMed ID: 33275747
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
Parikh RH; Lonial S
CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
[TBL] [Abstract][Full Text] [Related]
3. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
5. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cell therapy for multiple myeloma.
Wang Z; Chen C; Wang L; Jia Y; Qin Y
Front Immunol; 2022; 13():1050522. PubMed ID: 36618390
[TBL] [Abstract][Full Text] [Related]
7. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
Xu J; Ming X; Wang C; Xu B; Xiao Y
Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974
[TBL] [Abstract][Full Text] [Related]
8. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Anderson LD
Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
[TBL] [Abstract][Full Text] [Related]
9. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
Front Immunol; 2021; 12():755866. PubMed ID: 34777368
[TBL] [Abstract][Full Text] [Related]
10. Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function.
He SL; Cheng YH; Wang D; Xu ML; Que YM; Xu YJ; Ma LM; Li CR; Zhou JF
Curr Med Sci; 2021 Jun; 41(3):474-481. PubMed ID: 34169427
[TBL] [Abstract][Full Text] [Related]
11. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
Gagelmann N; Ayuk F; Atanackovic D; Kröger N
Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
[TBL] [Abstract][Full Text] [Related]
12. Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma.
Jindal V; Khoury J; Gupta R; Jaiyesimi I
Am J Clin Oncol; 2020 May; 43(5):371-377. PubMed ID: 31990758
[TBL] [Abstract][Full Text] [Related]
13. CAR T-cell therapy in multiple myeloma: more room for improvement.
Teoh PJ; Chng WJ
Blood Cancer J; 2021 Apr; 11(4):84. PubMed ID: 33927192
[TBL] [Abstract][Full Text] [Related]
14. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
15. [Future therapeutic strategies for multiple myeloma].
Ishida T
Rinsho Ketsueki; 2022; 63(6):635-645. PubMed ID: 35831199
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience of CAR T cells for multiple myeloma.
Simmons GL; Satta T; Castaneda Puglianini O
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101306. PubMed ID: 34625232
[TBL] [Abstract][Full Text] [Related]
17. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
Yang J; Zhou W; Li D; Niu T; Wang W
Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
[TBL] [Abstract][Full Text] [Related]
18. Recent updates on CAR T clinical trials for multiple myeloma.
Lin Q; Zhao J; Song Y; Liu D
Mol Cancer; 2019 Nov; 18(1):154. PubMed ID: 31684964
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
Choi T; Kang Y
Pharmacol Ther; 2022 Apr; 232():108007. PubMed ID: 34582835
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges.
Dhakal B; Hari PN; Usmani SZ; Hamadani M
Bone Marrow Transplant; 2021 Jan; 56(1):9-19. PubMed ID: 32770147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]